Home > Publications Database > The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets. > print

001     280916
005     20250921001952.0
024 7 _ |a 10.1038/s41590-025-02230-7
|2 doi
024 7 _ |a pmid:40826276
|2 pmid
024 7 _ |a 1529-2908
|2 ISSN
024 7 _ |a 1529-2916
|2 ISSN
024 7 _ |a altmetric:180392630
|2 altmetric
037 _ _ |a DZNE-2025-00999
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Weber, Alexander N R
|0 0000-0002-8627-7056
|b 0
245 _ _ |a The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets.
260 _ _ |a London
|c 2025
|b Springer Nature Limited
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1758101434_31853
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Understanding and treating inflammation has proven a formidable challenge. The initiator and central motor of inflammation, the protein NLRP3, is an innate immune sentinel and nonspecific sensor of cellular perturbation. A wide array of inflammatory triggers prompts the formation of an NLRP3 'inflammasome' complex, leading to inflammatory interleukin-1 family cytokine release and pyroptotic cell death. Since gain-of-function mutations in NLRP3 were demonstrated to cause a rare autoinflammatory disease termed cryopyrin-associated periodic syndrome, NLRP3 has emerged as key mediator of inflammation in mouse models for many common diseases, including atherosclerosis, Alzheimer's disease and gout. But even though small-molecule NLRP3 modulators have entered clinical development, many aspects of NLRP3 activation and regulation in humans remain relatively unclear. This Review summarizes the current understanding of the molecular mechanisms that drive NLRP3 inflammasome activation and regulation, and discusses emerging targeting strategies. Understanding these processes can guide precision medicine approaches aimed at mitigating NLRP3-driven pathologies.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a NLR Family, Pyrin Domain-Containing 3 Protein
|2 NLM Chemicals
650 _ 7 |a Inflammasomes
|2 NLM Chemicals
650 _ 7 |a NLRP3 protein, human
|2 NLM Chemicals
650 _ 2 |a NLR Family, Pyrin Domain-Containing 3 Protein: metabolism
|2 MeSH
650 _ 2 |a NLR Family, Pyrin Domain-Containing 3 Protein: genetics
|2 MeSH
650 _ 2 |a NLR Family, Pyrin Domain-Containing 3 Protein: immunology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Inflammasomes: metabolism
|2 MeSH
650 _ 2 |a Inflammasomes: immunology
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Cryopyrin-Associated Periodic Syndromes: immunology
|2 MeSH
650 _ 2 |a Cryopyrin-Associated Periodic Syndromes: drug therapy
|2 MeSH
650 _ 2 |a Cryopyrin-Associated Periodic Syndromes: genetics
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Inflammation: immunology
|2 MeSH
700 1 _ |a McManus, Róisín M
|0 P:(DE-2719)2811671
|b 1
700 1 _ |a Hornung, Veit
|0 0000-0002-4150-194X
|b 2
700 1 _ |a Geyer, Matthias
|0 0000-0002-7718-5002
|b 3
700 1 _ |a Kuemmerle-Deschner, Jasmin B
|b 4
700 1 _ |a Latz, Eicke
|0 P:(DE-2719)2000062
|b 5
|u dzne
773 _ _ |a 10.1038/s41590-025-02230-7
|g Vol. 26, no. 9, p. 1453 - 1466
|0 PERI:(DE-600)2026412-4
|n 9
|p 1453 - 1466
|t Nature immunology
|v 26
|y 2025
|x 1529-2908
856 4 _ |u https://pub.dzne.de/record/280916/files/DZNE-2025-00999_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/280916/files/DZNE-2025-00999_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:280916
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2811671
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 5
|6 P:(DE-2719)2000062
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-13
|w ger
915 _ _ |a DEAL Nature
|0 StatID:(DE-HGF)3003
|2 StatID
|d 2024-12-13
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT IMMUNOL : 2022
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-13
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-13
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-13
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-13
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b NAT IMMUNOL : 2022
|d 2024-12-13
920 1 _ |0 I:(DE-2719)1013042
|k AG McManus
|l Translational Neuroimmunology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1013042
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21